Gynecologic Cancers | Topics

Marina Frimer, MD, Talks Future Treatments in Uterine Cancer
April 19, 2022

Marina Frimer, MD, spoke about what the future holds for the treatment of patients with platinum-sensitive recurrent uterine cancer.

NG-641 Plus Nivolumab to be Assessed in Previously Treated Metastatic or Advanced Epithelial Tumors
April 13, 2022

The safety and efficacy of NG-641 plus nivolumab will be assessed as part of the phase 1a/b NEBULA trial in patients with previously treated metastatic or advanced epithelial tumor.

ZN-c3 Yields Promising Preliminary Results in Recurrent/Advanced Uterine Serous Carcinoma
April 12, 2022

Patients with advanced or recurrent uterine serous carcinoma derived promising benefit from treatment with ZN-c3.

Marina Frimer, MD, Discusses Maintenance Niraparib in Platinum-Sensitive Uterine Serous Cancer
March 31, 2022

Marina Frimer, MD, spoke about the goals of a phase 2 trial and how it can impact patients with platinum-sensitive recurrent uterine serous carcinoma.

Addition of Durvalumab to CRT Did Not Significantly Improve PFS vs CRT Alone in Locally Advanced Cervical Cancer
March 25, 2022

Patients with locally advanced cervical cancer did not see further benefit from the addition of concurrent durvalumab to chemoradiotherapy.

Matulonis Provides Overview of Gynecologic Treatment Landscape Advances
March 11, 2022

“Team science is important for being open-minded [and] thinking outside of the box.”

Cemiplimab Achieves Promising Survival in Recurrent Cervical Cancer
February 14, 2022

Patients with recurrent cervical cancer appeared to achieve a promising survival benefit following treatment with cemiplimab.

Frontline Maintenance Selinexor Yields Significant PFS Benefit in Advanced or Recurrent Endometrial Cancer
February 08, 2022

The phase 3 SIENDO trial, examining the use of frontline maintenance selinexor after combination chemotherapy in patients with advanced or recurrent endometrial cancer, met its primary end point of a statistically significant improvement in progression-free survival.

Outpatient Identification of High-Risk Gynecologic Cancers Increased Timely Goals of Care Conversations
February 06, 2022

Researchers prospectively analyzed the effect of implementing systemic outpatient identification on initiating goals of care conversations for high-risk patients with gynecologic cancers.

NCCN Raises Awareness of Disparities in Cervical Cancer Outcomes for World Cancer Day
February 04, 2022

In recognition of World Cancer Day, CancerNetwork® spotlights NCCN efforts to reduce disparities in cervical cancer.